Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 1
2015 5
2016 4
2017 2
2018 3
2019 5
2020 5
2021 9
2022 11
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: ko r. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K. Saito R, et al. Among authors: ko r. Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36966696 Free article. Clinical Trial.
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, Tanizaki J, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K. Asao T, et al. Among authors: ko r. Clin Lung Cancer. 2023 Nov;24(7):e247-e253. doi: 10.1016/j.cllc.2023.05.004. Epub 2023 May 19. Clin Lung Cancer. 2023. PMID: 37316381 Clinical Trial.
Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: ko r. Thorac Cancer. 2022 Jul;13(14):2064-2074. doi: 10.1111/1759-7714.14529. Epub 2022 Jun 13. Thorac Cancer. 2022. PMID: 35698259 Free PMC article. Review.
A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1.
Wirawan A, Tajima K, Takahashi F, Mitsuishi Y, Winardi W, Hidayat M, Hayakawa D, Matsumoto N, Izumi K, Asao T, Ko R, Shimada N, Takamochi K, Suzuki K, Abe M, Hino O, Sekido Y, Takahashi K. Wirawan A, et al. Among authors: ko r. Mol Cancer Res. 2022 Jan;20(1):127-138. doi: 10.1158/1541-7786.MCR-21-0230. Epub 2021 Sep 30. Mol Cancer Res. 2022. PMID: 34593606
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Nishioka N, et al. Among authors: ko r. Thorac Cancer. 2022 May;13(10):1496-1504. doi: 10.1111/1759-7714.14421. Epub 2022 Apr 14. Thorac Cancer. 2022. PMID: 35420262 Free PMC article.
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K, Suina K, Shukuya T, Takahashi F, Hayashi T, Hara K, Saito T, Mitsuishi Y, Shimamura SS, Winardi W, Tajima K, Ko R, Mimori T, Asao T, Itoh M, Kawaji H, Suehara Y, Takamochi K, Suzuki K, Takahashi K. Kanamori K, et al. Among authors: ko r. Thorac Cancer. 2023 Apr;14(12):1089-1097. doi: 10.1111/1759-7714.14853. Epub 2023 Mar 16. Thorac Cancer. 2023. PMID: 36924358 Free PMC article.
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K. Mimori T, et al. Among authors: ko r. Cancers (Basel). 2022 Jan 11;14(2):331. doi: 10.3390/cancers14020331. Cancers (Basel). 2022. PMID: 35053494 Free PMC article.
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.
Doshita K, Kenmotsu H, Omori S, Tabuchi Y, Kawabata T, Kodama H, Nishioka N, Miyawaki E, Iida Y, Miyawaki T, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Kaneko T, Takahashi T. Doshita K, et al. Among authors: ko r. Invest New Drugs. 2022 Apr;40(2):411-419. doi: 10.1007/s10637-021-01183-6. Epub 2021 Oct 30. Invest New Drugs. 2022. PMID: 34716848
48 results